Form 4: Roivant CEO Eric Venker Exercises, Sells Shares

Roivant Sciences Ltd.'s President and Immunovant CEO, Eric Venker, exercised stock options and subsequently sold 200,000 common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported transactions on December 9, 2025.
• Exercised 200,000 stock options at an exercise price of $3.85 per common share.
• Subsequently sold 200,000 common shares at a weighted average price of $20.85 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
• Following these transactions, Venker directly beneficially owns 1,497,908 common shares and 5,876,523 stock options.
• The stock options have a vesting commencement date of April 20, 2022, vesting 25% on the first anniversary and then in 36 equal monthly installments.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which mitigates any negative sentiment typically associated with insider selling. The executive realized a substantial profit from the option exercise.

Positives

• The executive realized a significant profit from the option exercise and subsequent sale, with a sale price of $20.85 compared to an exercise price of $3.85.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• An insider sale of 200,000 common shares, even under a 10b5-1 plan, represents a reduction in the executive's direct equity holdings.

Risks

• While executed under a 10b5-1 plan, significant insider selling can sometimes be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify personal holdings.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, though the pre-arranged 10b5-1 plan mitigates concerns about discretionary selling based on new information.

Key Dates

Recommendation

The Form 4 filing details a pre-scheduled insider transaction (exercise of options and subsequent sale of shares) under a Rule 10b5-1 plan. Such transactions are generally considered routine and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The executive realized a significant profit, which is positive for them personally, but the sale itself is a planned event.

Keywords

Roivant Sciences, ROIV, Eric Venker, Form 4, insider trading, stock options, share sale, 10b5-1 plan